Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Webinar Archive – The Future of CAR-T Therapy: Can CAR-T Cure CLL?

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

CLL Society Webinar Archive – The Future of CAR-T Therapy: Can CAR-T Cure CLL?

Recorded November 17, 2020.


Patty Koffman
Co-founder and Communications Director
CLL Society


Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
CLL Society


Joseph A. Fraietta, PhD
Joseph A. Fraietta, PhD
Assistant Professor of Microbiology
Perelman School of Medicine
Philadelphia, PA

Dr. Fraietta has developed novel approaches for the treatment of cancer through genetic modification of T lymphocytes that contributed to the initiation of multiple clinical trials and FDA approval of the first CAR T cell therapy. In 2015, Dr. Fraietta assumed the directorship of a research laboratory in the first-of-its-kind Center for Advanced Cellular Therapies where his group led initiatives to use CAR-T cell infusion products for key biomarkers and mechanisms of potency, with the objective of predicting clinical responses to adoptive cell therapies. He now directs the Tumor Immunotherapy Laboratory as a faculty member in the same center.


CAR-T is a revolutionary therapy in CLL and other blood cancers. As part of the team led by Dr. Carl June at U. Penn, Dr. Joe Fraietta’s translational research has taken CAR-T from an exciting possibility to a lifesaving “living drug”. Don’t miss this opportunity to be able to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers.

This program was made possible by the support of Adaptive Biotechnologies, Bristol Meyers Squibb, Genentech, and Novartis.